Grant: Undergraduate: Mobility, musculoskeletal health & arthritis - IA
University of Winnipeg
$4,950.00
Axon Diameter Distributions as an Early Biomarker for Apraxia in Alzheimer's Disease.
FY 2012-13
Summary
I am creating a Magnetic Resonance Imaging method which will be able to identify an early biomarker for Apraxia in Alzheimer's disease. Ultimately the method can be used to monitor objectively the effects of therapeutics to determine the efficacy of treatment in real time. The ability to monitor brain changes in live beings will enhance the development and delivery of treatments. For instance, monitoring the response to treatments of the newly discovered biomarker of Alzheimer's disease will help us to develop new treatments for the disease that can be delivered earlier in the disease course. The aim is to slow down or completely halt the progress of the disease.
Department
Program
Undergraduate: Mobility, musculoskeletal health & arthritis - IA
Recipient
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
283362
Name
Vincent Trevor J
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Undergraduate: Mobility, musculoskeletal health & arthritis - IMHA
Projecttitle
Axon Diameter Distributions as an Early Biomarker for Apraxia in Alzheimer's Disease.
Programtype2
Studentship Programs
Orgnameinp2
University of Winnipeg
Cihramount2
$4,950
Cihrequipment2
$0
Programname2
Undergraduate: Mobility, musculoskeletal health & arthritis - IA
Keyworddelim
Alzheimer'S Disease; Apraxia; Axon Diameter Distribution; Computer Simulation; Diffusion Tensor Imaging; Early Biomarkers; Magnetic Resonance Imaging; Mouse Model
Abstract
I am creating a Magnetic Resonance Imaging method which will be able to identify an early biomarker for Apraxia in Alzheimer's disease. Ultimately the method can be used to monitor objectively the effects of therapeutics to determine the efficacy of treatment in real time. The ability to monitor brain changes in live beings will enhance the development and delivery of treatments. For instance, monitoring the response to treatments of the newly discovered biomarker of Alzheimer's disease will help us to develop new treatments for the disease that can be delivered earlier in the disease course. The aim is to slow down or completely halt the progress of the disease.
Competitiondate
201301
Approvedterm2
0 yr 3 mths
Pinamesdelim
Vincent, Trevor J
Approvedterm
0 an 3 mois
Cihrcontribution2
~ $4,950~ $0~
